Tyra Biosciences (TYRA) to Release Earnings on Wednesday

Key Points

• Tyra Biosciences is set to release its Q2 2025 earnings results on August 6th, with analysts predicting earnings of ($0.53) per share.
• Recent reports indicate that multiple analysts have given the company an average buy rating and set a target price of $30.83 for its shares.
• In a significant insider transaction, Director Gilla Kaplan sold 30,000 shares at an average price of $10.31, reducing her position by 33.47%.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) is anticipated to post its Q2 2025 quarterly earnings results before the market opens on Wednesday, August 6th. Analysts expect Tyra Biosciences to post earnings of ($0.53) per share for the quarter.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.47) earnings per share for the quarter, topping analysts' consensus estimates of ($0.49) by $0.02. On average, analysts expect Tyra Biosciences to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Tyra Biosciences Stock Performance

Shares of Tyra Biosciences stock traded down $0.56 on Friday, reaching $10.37. 283,932 shares of the stock were exchanged, compared to its average volume of 226,927. The firm's 50 day moving average is $10.10 and its 200-day moving average is $10.75. Tyra Biosciences has a one year low of $6.42 and a one year high of $29.60. The firm has a market cap of $550.54 million, a PE ratio of -6.36 and a beta of 1.08.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. HC Wainwright reiterated a "buy" rating and set a $30.00 price objective on shares of Tyra Biosciences in a research report on Tuesday, July 1st. Piper Sandler assumed coverage on shares of Tyra Biosciences in a research report on Wednesday, May 21st. They set an "overweight" rating and a $33.00 price objective for the company. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Tyra Biosciences currently has an average rating of "Buy" and a consensus target price of $30.83.

Insider Activity at Tyra Biosciences

In related news, Director Gilla Kaplan sold 9,568 shares of the stock in a transaction on Wednesday, June 18th. The shares were sold at an average price of $9.78, for a total transaction of $93,575.04. Following the transaction, the director directly owned 28,231 shares of the company's stock, valued at $276,099.18. This represents a 25.31% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last 90 days, insiders have sold 61,392 shares of company stock valued at $628,358. Corporate insiders own 15.20% of the company's stock.

Institutional Trading of Tyra Biosciences

Institutional investors and hedge funds have recently made changes to their positions in the company. Jane Street Group LLC bought a new position in Tyra Biosciences during the first quarter worth about $324,000. Goldman Sachs Group Inc. grew its stake in Tyra Biosciences by 21.7% during the first quarter. Goldman Sachs Group Inc. now owns 78,006 shares of the company's stock valued at $725,000 after acquiring an additional 13,896 shares in the last quarter. Woodline Partners LP purchased a new position in Tyra Biosciences during the first quarter valued at approximately $931,000. Finally, Millennium Management LLC grew its stake in Tyra Biosciences by 28.2% during the first quarter. Millennium Management LLC now owns 404,165 shares of the company's stock valued at $3,759,000 after acquiring an additional 89,024 shares in the last quarter. Hedge funds and other institutional investors own 84.14% of the company's stock.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.